ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0554

Reverse Signaling Through PD-L1 Plays a Central Role in Extracellular Matrix Protein Secretion from Cutaneous Myofibroblasts in Systemic Sclerosis

Maithri Aspari1, Stinne Greisen1, Malene Hvid1, Klaus Sondergaard2, Voon Ong3, Christopher Denton4, David Abraham5 and Bent Deleuran1, 1Aarhus University, Aarhus, Denmark, 2Aarhus University Hospital, Aarhus, Denmark, 3University College London Medical School Royal Free Campus, London, United Kingdom, 4University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 5University College London, London, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Myofibroblasts, PD1, PDL1, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The PD-1/PD-L1 pathway has been implicated in Systemic Sclerosis (dSSc). This disease is dominated by increased extracellular matrix deposition initiated by myofibroblasts. We therefore examined the PD-1/PD-L1 pathway in dSSc myofibroblasts and its influence on fibrosis.

Methods: Dermal fibroblasts were isolated from the skin from patients with dSSc (n=9) and compared with dermal fibroblasts from healthy controls (HC)(n=4). Cells were stimulated with TGF β for 48 hours and analyzed by flow cytometry for expression of the surface proteins CD45, Thymocyte differentiation antigen-1 /(CD90 Thy-1), podoplanin (PDPN), Programmed Death Protein Ligand-1(PD-L1), Fibroblast activation Protein (FAP),and Intercellular adhesion molecule-1 (ICAM-1) and alpha smooth muscle actin (α- SMA). Supernatants were analyzed for the production of Type 1 Procollagen and IL-6. Parallel to this, dcSSc fibroblasts, were stimulated with IFNγ (10ng/ml) for 48 hours followed by addition of anti-PD-L1 antibody (atrezolizumab, 5ug/ml) and soluble, recombinant PD-1 (RPD-1;1ug/ml). Supernatants were harvested after 48 hours and analyzed for production of Type 1 Procollagen and Fibronectin.

Results: CD45neg fibroblasts, from both dSSc as well as HC could be identified by their expression of Thy-1 and Podoplanin. Upon stimulation with TGFβ, fibroblasts from dSSc patients increased the percentages of myofibroblasts expressing PD-L1, α- SMA, ICAM-1, FAP and Podoplanin when compared to HC fibroblasts.(Figure 1) All p < 0.05, Figure 1. Upon concatenating and analyzing this data by tSNE, we could demarcate a distinct populations of the myofibroblasts that had a high expression of PD-L1 together with ICAM-1 (Figure 2). Compared with HC, dcSSc fibroblasts were characterized by an increased production of Type 1 Procollagen and IL -6, this was highly increased by stimulation with TGFβ, still most pronounced in dSSc (Figure 3a). To explore the role of PD-L1 in fibrosis, we added an anti-PD-L1 monoclonal antibody, or rPD-1 to fibroblasts. Both increased the production of Type 1 Pro-collagen, whereas fibronectin was only increased by adding the anti-PD-L1 antibody(Figure 3b).

Conclusion: dSSc fibroblasts are distinct from dermal fibroblasts from HC, both in their phenotype and functionality. The myofibroblast population can thus be defined as a subset within the dSSc fibroblasts with high and co-expression of PD-L1, FAP, Podoplanin, and ICAM. PD-L1 plays an important role in regulating fibrosis, and inflammation in dSSc and our results supports the notion that PD-L1 does this through reverse signaling.

Figure 1: Fibroblast from dSSc fibroblasts increased PD-L1, a-SMA, ICAM_1, FAP and PDPN compared with HC after stimulation with TGFb for 48h.

A t-SNE analysis of concatenated dSSc fibroblasts populations that were CD90 positive with overlay of markers of fibroblast activation such as Podoplanin, FAP and intracellular expression of Alpha SMA. A distinct myofibroblast population could be identified that express the above markers together with PD-L1 and ICAM_1.

Increased type 1 collagen production (a) and IL-6 (b) by dSSc fibroblasts when compared with healthy controls (HC), with or without stimulation by TGFb.
Type 1 procollagen (c) and fibronectin (d) production after addition of an anti-PD-L1 antibody or sPD_1 in dSSc fibroblasts.


Disclosures: M. Aspari, None; S. Greisen, None; M. Hvid, None; K. Sondergaard, None; V. Ong, None; C. Denton, Acceleron, 2, 6, Actelion, 2, 6, Arxx Therapeutics, 2, 6, Boehringer Ingelheim, 2, 6, Bristol-Myers Squibb, 2, 6, Corbus, 2, 6, CSL Behring, 2, 6, Galapagos NV, 2, 6, GlaxoSmithKline, 2, 6, Horizon, 2, 6, Inventiva, 2, 6, Roche, 2, 6, Sanofi, 2, 6, Servier, 2; D. Abraham, None; B. Deleuran, None.

To cite this abstract in AMA style:

Aspari M, Greisen S, Hvid M, Sondergaard K, Ong V, Denton C, Abraham D, Deleuran B. Reverse Signaling Through PD-L1 Plays a Central Role in Extracellular Matrix Protein Secretion from Cutaneous Myofibroblasts in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/reverse-signaling-through-pd-l1-plays-a-central-role-in-extracellular-matrix-protein-secretion-from-cutaneous-myofibroblasts-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reverse-signaling-through-pd-l1-plays-a-central-role-in-extracellular-matrix-protein-secretion-from-cutaneous-myofibroblasts-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology